Clinical Trials (TRIDENT) Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With Radiation Therapy Temozolomide for the Treatment of Newly Diagnosed GBM (EF-32)

(TRIDENT) Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With Radiation Therapy Temozolomide for the Treatment of Newly Diagnosed GBM (EF-32)

To test the effectiveness and safety of Optune® given concomitantly with radiation therapy (RT) and temozolomide (TMZ) in newly diagnosed GBM patients, compared to radiation therapy and temozolomide alone. In both arms, Optune® and maintenance temozolomide are continued following radiation therapy.

Inclusions/Exclusions: Measurable disease by RANO. KPS 60 or greater.

Learn More